CancerVista

Earlier detection.
Confident decisions.

A ctDNA liquid biopsy that detects solid tumor recurrence months before imaging can confirm it.

Request Protocol Speak with a Specialist

Clinical Validation

Built on rigorous evidence

>99%

Sensitivity

At ≥1% VAF threshold

96.7%

Specificity

MRD detection at 2.5×10⁻⁵ threshold

2–4

Weeks

Turnaround time for an interpreted report

The Clinical Gap

Know before imaging can show you

ctDNA detects recurrence a median of 5+ months before CT imaging confirms it.

Based on published colorectal cancer MRD studies.

A patient completes curative resection. CEA is normal. CancerVista detects ctDNA at month 3. CT confirms recurrence at month 8.

What CancerVista Enables

Decisions you couldn't make before

Act before imaging confirms it Detect minimal residual disease months before CT or PET can show recurrence. Intervene when treatment is most effective.

Know if therapy is working Monitor ctDNA levels across treatment cycles to assess response — without waiting for the next imaging appointment.

Detect relapse before symptoms Identify recurrence in the asymptomatic window. Give patients the best chance of curative-intent retreatment.

Stratify risk with confidence Use post-surgical ctDNA status to distinguish patients who need intensive follow-up from those who can be safely monitored.

Coverage

16 solid tumor types

Does it cover your patients? Find your tumor type:

Bladder Brain Breast Cervical Colorectal Esophageal Head & Neck Kidney Liver Lung Ovarian Pancreatic Prostate Skin Stomach Thyroid

How It Works

Three steps. Everything else is handled.

Send a blood sample

Draw 20ml of peripheral blood from your patient. Ship using our standard collection kit. No specialized lab setup required.

We sequence and analyze

Our laboratory performs targeted sequencing and bioinformatic analysis. Patient-specific mutations are tracked across timepoints.

You receive an interpreted report

A Liqomics specialist interprets the results in clinical context and delivers a clear, actionable report within 2–4 weeks.

Dr. Sven Borchmann, Founder & CEO of Liqomics

From the Founder

Built by an oncologist, for oncologists

"I've treated patients whose recurrence I missed until imaging confirmed what the blood had been showing for months. CancerVista exists to close that window."

Dr. Sven Borchmann, MD Founder & CEO, Liqomics

Get Started

Detect recurrence. Earlier.

Request our test protocol or speak directly with a Liqomics specialist.

Request Protocol →

References

¹ Jácome & Johnson. "Minimal Residual Disease in Colorectal Cancer: Are We Finding the Needle in a Haystack?" (2023)
² Sabit, Attia & Mohamed et al. "Beyond traditional biopsies: the emerging role of ctDNA and MRD on breast cancer diagnosis and treatment" (2025)
³ Boukouris, Michaelidou & Joosse et al. "A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer" (2025)

Earlier detection.Confident decisions.